Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Pharma Mar, S.A
Woman Max 99 years
Pharma Mar, S.A
Update Il y a 4 ans
Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis®) en association avec l’oxaliplatine chez des patientes atteintes d’un cancer de l’ovaire avancé prétraité
Phase Ib Phase Ib stage: To determine the recommended dose (RD) of the combination of trabectedin and oxaliplatin in patients with advanced ovarian cancer. Phase II Phase II stage: To determine ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pharma Mar, S.A
Update Il y a 4 ans
Ensayo clínico y farmacocinético de fase II de infusión de 30 minutos de PM02734 (Irvalec®) cada tres semanas en pacientes con cáncer no microcítico de pulmón (CNMP) epidermoide previamente tratado con al menos una línea de quimioterapia con platino
Evaluar la actividad antitumoral de PM02734 administrado como infusión i.v. de 30 minutos cada tres semanas en pacientes con CPNM tratado previamente con al menos una línea de quimioterapia basada en ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pharma Mar, S.A
Update Il y a 4 ans
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC)
To determine a difference in PFS by an Independent Review Committee (IRC) between lurbinectedin (PM01183)/DOX and a control arm consisting of best Investigator’s choice between CTX, DOX and VCR (CAV)...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Pharma Mar, S.A
Update Il y a 4 ans
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer. Ensayo Clinico de Fase II de PM01183 en Cáncer de Mama Metastático Asociado o No a Mutación de Genes BRCA-1/2
To assess the antitumor activity of PM01183 in terms of overall response rate (ORR) according to RECIST vs 1.1 in each cohort of metastatic breast cancer (MBC) patients. Evaluar la actividad ant...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2